Britain’s medicine regulator approved Novo Nordisk’s oral weight-loss pill on Thursday, June 11, making the UK the first market in Europe where patients can access the treatment. According to Reuters, the regulatory clearance provides an alternative to injections for more than 10 million people living with obesity in the UK, intensifying competition between Novo Nordisk and U.S. rival Eli Lilly in the global pharmaceutical market.
Active Ingredients and Comparison With Injectables
The newly approved tablet contains semaglutide, which is the same active ingredient found in Novo Nordisk’s existing blockbuster injectable drugs, Wegovy for weight loss and Ozempic for diabetes. According to Reuters, the availability of an oral option is designed to appeal directly to patients who are reluctant to use injections. Industry analysts project that the global obesity drug market will exceed $100 billion in revenue by 2030, driven heavily by these expanding administration methods.
The rollout follows early approvals and launches in the United States, where Novo Nordisk introduced its pill earlier this year. Eli Lilly quickly followed suit in the U.S. market by launching its own oral medication, Foundayo, after receiving regulatory clearance in April. Both pharmaceutical companies are racing to capture European market share as regional regulators evaluate oral alternatives.
Clinical Considerations and Administration Guidelines
According to Dr. Marie Spreckley of the University of Cambridge, cited by Reuters, the tablet must be taken on an empty stomach and 30 minutes before eating.
“The key questions now relate to access, uptake, long-term adherence, and how best to integrate this treatment into routine care pathways,” Dr. Spreckley told Reuters.
Adding to this perspective, Danielle Brightman, clinical director at UK-based private digital healthcare platform Numan, noted in Reuters reporting that “oral GLP-1s will bring more people into treatment and give patients greater choice, but they are not silver bullets.”
Access Pathways and Private-Pay Market Realities
While the regulatory approval grants immediate clearance, the pathway to state-funded healthcare remains under review. Data from IQVIA cited by Reuters shows that approximately 2.4 million people in the UK used GLP-1 medications last year, but only about 200,000 of those individuals accessed their treatments through the state-run National Health Service (NHS). The vast majority of users obtained their prescriptions via private healthcare providers, where the drugs can cost hundreds of pounds a month.
Before the oral treatment can be prescribed through the NHS, Britain’s National Institute for Health and Care Excellence (NICE) must assess the pill. A NICE spokesperson stated to Reuters that the agency is currently in active discussions with Novo Nordisk, though the company must still make an evidence submission for the institute to make a recommendation.
In the interim, patients seeking access to the Wegovy pill must do so through private healthcare providers, which will control its price, according to statements from Novo Nordisk reported by Reuters.
Worth a look